Abstract : Factors contributing to mortality in healthcare-associated pneumonia HCAP have not been investigated fully. We reviewed the etiology and identi ed prognostic factors of HCAP in hospitalized patients. We conducted a retrospective study of 500 Japanese patients with HCAP to assess these factors, with special emphasis on microbial etiology. Patients with HCAP were older 73.4 11.4 years , more predominantly male 74.4 , and had more smoking history and comorbidity than did community-acquired pneumonia CAP patients. Microbes were identi ed in 52.8 of HCAP patients. The most frequent causative microbial agents were Streptococcus pneumoniae n 108, 21.6 , influenza virus n 47, 9.4 , and Pseudomonas aeruginosa n 40, 8.0 . Multiple drug-resistant MDR pathogens were more frequent in HCAP patients 9.8 than CAP patients. Overall, 47 HCAP patients 9.4 died, with mortality being higher in HCAP than CAP patients. The three leading causes of non-survival from HCAP were S. pneumoniae, in uenza virus, and P. aeruginosa. MDR pathogens accounted for 21.3 of non-survivors. Multivariate analysis revealed disease severity on admission and treatment failure of initial antibiotics as independent factors for 30-day mortality. Among patients with treatment failure of initial antibiotics, 29.9 had received appropriate antibiotics. The most frequent pathogens in HCAP were S. pneumoniae, in uenza virus, and P. aeruginosa, in both survivors and nonsurvivors. Disease severity on admission and treatment failure of initial antibiotics were independent factors for mortality. MDR pathogens are important therapeutic targets to mitigate negative results, and treatment strategies other than antibiotic selection are also required.
Introduction
The 2005 guidelines of the American Thoracic Society / Infectious Diseases Society of America ATS / IDSA established the concept of healthcare-associated pneumonia HCAP , describing a patient population with frequent healthcare contacts and therefore at high risk of contracting resistant organisms 1 . Data supporting the HCAP concept were derived from a retrospective recent studies evaluating the etiology in patients with HCAP, the incidence of MDR pathogens was far lower than that reported in the previous study 2 .
HCAP patients are older and have a higher frequency of comorbidity [2] [3] [4] than patients with community-acquired pneumonia CAP , and chronic conditions in older adults are known to increase the risk of in uenza complications. Thus, we assumed that in uenza virus infection is not uncommon in HCAP ; however, few studies have investigated the frequency of influenza virus infection in this condition. Thus, the aims of this study were to review the microbial etiology and frequency of in uenza virus infection in HCAP and to identify factors contributing to mortality in patients with this disease.
Materials and methods
We performed a retrospective study of all patients hospitalized with HCAP at our institution in Saitama, Japan, from January 2002 to December 2011. Characteristics of HCAP patients were compared with those of CAP patients hospitalized in our institution during the same period 5 .
The study protocol was approved by the Ethics Committee of the Saitama Cardiovascular and Respiratory Center 2011027 . Pneumonia was diagnosed on the basis of symptoms suggestive of lower respiratory tract infection and the development of in ltration on chest X-ray. HCAP was defined when the criteria of the ATS / IDSA guidelines 1 were satisfied Table 1 , and severe HCAP was defined when at least one major criterion or three minor criteria of the IDSA / ATS guidelines 6 were present. Patients with acquired immunodeficiency syndrome, tuberculosis, non-resected lung cancer, or a con rmed alternative diagnosis at the end of followup were excluded from the study. Diagnosis of causative microorganisms was based on the results of semiquantitative cultures of respiratory samples or blood, paired sera, urinary antigen tests for Streptococcus pneumoniae and Legionella pneumophila, and nasopharyngeal swabs for influenza virus as reported previously 5 . In this study, MDR pathogens included methicillin-resistant Staphylococcus aureus MRSA , Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and extended-spectrum -lactamase-producing Enterobacteriaceae, based on previous reports showing problematic clinical outcomes for infections caused by these pathogens 1, 7 .
Treatment prescribed during the rst 24 h of hospitalization was considered the initial treatment. Concordant CAP therapy was de ned according to established IDSA / ATS guidelines 6 .
The treatment effect of initial antibiotics after admission was judged after the rst 48 72 h of therapy, based on body temperature, arterial oxygen saturation measured with pulse oximeter SpO 2 or arterial partial pressure of oxygen, and white blood cell count 8 . In cases of treatment failure, the appropriateness of administered antibiotics was judged by the in vitro susceptibility of cultured bacteria and coverage of atypical pathogens and in uenza virus.
Variables assessed as possible risk factors for 30-day mortality of HCAP included : patient demographic factors, the presence of the comorbid diseases listed in Table 2 , the presence of prior antibiotics administered by a local physician, causative pathogens, disease severity on admission, and initial treatment antibiotics.
Statistical analysis
Results are presented as the number and percentage or mean standard deviation unless otherwise indicated. Risk factors for mortality from HCAP were evaluated by univariate and multivariate logistic regression analysis. Variables showing signi cance by univariate analysis were included in the multivariate logistic regression analysis with backward elimination method. The 95 con dence interval CI for all comparisons is also reported. In all instances, a 2-tailed P value of 0.05 was considered to indicate statistical signi cance. All statistical analyses were performed with Statistical Analysis System software SAS version 9.1.3 ; SAS Institute, Inc., Cary, NC .
Results
Overall, 500 patients were enrolled during the study period. Characteristics of the patients diagnosed as having HCAP are shown in Table 2 . Patients with HCAP were older, more predominantly male, had more smoking history, more comorbidity, and had more frequently received long-term oxygen therapy and antibiotics prior to admission to our hospital than did patients with CAP.
Microbiological patterns
Diagnostic methods used and results obtained positive cases / number tested are listed in Table 3 . The etiologic microorganisms of HCAP are shown in Table 4 . Of the 264 patients 52.8 with a pathogen identified, 40 had two or three pathogens. S. pneumoniae was the most frequent microorganism found in polymicrobial infections, with S. pneumoniae and in uenza virus being the most frequent combination Table 5 . Among these 47 patients, only 8 had received in uenza vaccination. There were no differences in the rates of etiology of single pathogens, polymicrobial infections, and unknown pathogens between CAP and HCAP patients P 0.29 . MDR pathogens and atypical pathogens were found in 9.8 and 9.0 of patients, respectively. The frequency of MDR pathogens differed between HCAP and CAP HCAP, 9.0 versus CAP, 3.4 , and atypical pathogens were more frequent in CAP than HCAP.
Etiology of severe HCAP
In the 93 patients with severe HCAP, the three most frequently isolated pathogens were S. pneumoniae, influenza virus, and P. aeruginosa. MDR pathogens and atypical pathogens were found in 15.1 and 9.7 of patients, respectively, and polymicrobial infections occurred in 15.1 of patients. In 10 of 13 patients with influenza virus infection, the virus was detected by RIDTs ; paired sera could only be obtained in 6 patients and increased antibody titers were found in 4 patients. 
Initial antibiotic treatment after admission
Of the 500 patients with HCAP, 296 59.2 received two or three antibiotics. An antipseudomonal drug was administered as initial antibiotic therapy in 38.6 of patients, and none received an anti-MRSA agent. Thus, according to the ATS / IDSA guidelines for HCAP, therapy was discordant in all patients 1 . In contrast, therapy concordant with CAP guidelines was administered to 304 of the HCAP patients 61.0 -lactams plus macrolides, n 258 ; plus tetracyclines, n 10 ; uoroquinolones with / without -lactams and macrolides, n 36 , while it was not administered to 196 patients -lactams only, n 184 ; macrolides only, n 6 ; tetracyclines only, n 2 ; -lactams plus clindamycin, n 4 .
Neuraminidase inhibitors for in uenza virus infection
Neuraminidase inhibitors NIs were administered to 33 of 47 patients 70.2 with in uenza virus infection, based on positive RIDT results in 30 patients and clinical ndings with a negative RIDT result in 3 patients. Fourteen of the 30 patients received NIs within 48 h after onset based on RIDT results, whereas 3 patients received NIs within 48 h after onset based on clinical ndings.
Outcomes
Treatment with initial antibiotics failed in 97 patients 19.4 . Of these 97 patients, 29 29.9 received appropriate antibiotics. Overall, 47 HCAP patients 9.4 died. Among the 49 patients with MDR pathogen infections, treatment failure with initial antibiotics occurred in 18 patients P. aeruginosa, n 14 ; MRSA, n 1 ; extended-spectrum -lactamase-producing Gram-negative enteric bacilli, n 1 ; MRSA S. maltophilia, n 1 ; MRSA P. aeruginosa, n 1 . Among these 18 patients, 10 patients died, of whom 5 had received appropriate antibiotics. Mortality from HCAP was higher than that from CAP. The most frequently isolated pathogens in non-survivors were S. pneumoniae, P. aeruginosa, and influenza virus. MDR pathogens and atypical pathogens were found in 23.4 and 8.5 of non-survivors, respectively, and polymicrobial infection occurred in 12.8 of non-survivors. All 6 cases of in uenza virus infection in nonsurvivors were detected by RIDT, but paired sera could only be obtained in 2 cases. Among the 6 non-survivors with in uenza virus infection, 5 had not received in uenza vaccination, 2 had not received NIs, and the remainder had received NIs 48 h or more after onset Table 6 .
Risk factors for mortality
Multivariate analysis revealed disease severity and failure of initial antibiotic therapy as independent risk factors for mortality Table 7 . CAP therapy was not associated with improved mortality by univariate analysis. Congestive heart failure, MRSA infection, and MDR pathogen infection were signi cant factors by univariate analysis but were nonsigni cant factors by multivariate analysis. Infection with S. pneumoniae odds ratio, 0.725 ; 95 CI, 0.283-1.639 ; P 0.55 , P. aeruginosa odds ratio, 2.691 ; 95 CI, 1.001-6.508 ; P 0.05 , and in uenza virus odds ratio, 1.469 ; 95 CI, 0.481-3.774 ; P 0.54 were not signi cant factors by univariate analysis.
Discussion
We found that patients with HCAP and CAP differed in demographics, disease etiology and severity, and mortality. In the patients with HCAP, the most frequent microbial agents were S. pneumoniae, P. aeruginosa, and in uenza virus. Severity on admission and treatment failure of initial antibiotics were independent risk factors for mortality.
S. aureus is reported to be the most frequent pathogen 46.7 of HCAP, followed by P. aeruginosa 25.3 , Klebsiella pneumoniae 7.6 , and others 2 . However, only culture-positive cases were analyzed. In the present study, urinary antigen tests, serological analysis, and RIDT were also used in the etiological diagnosis, with cases of unknown etiology also included. More recent studies have revealed that the most frequent pathogen is S. pneumoniae, and atypical pathogens have been detected in 0.7 to 16.1 of cases 3, 4, [9] [10] [11] [12] . In the present study, S.
pneumoniae was the most frequent pathogen of HCAP, and the frequency of atypical pathogens was 9.0 , results compatible with those of previous reports 3, 4, [9] [10] [11] [12] . Although the frequency of atypical pathogens was lower in HCAP than in CAP, the 9.0 incidence of atypical pathogens should not be ignored. The third leading pathogen was P. aeruginosa, indicating it to be certainly a major pathogen of HCAP. We adopted RIDT and serological analysis to detect influenza virus infection as reported previously 5 . Previous studies have relied on the measurement of antibodies in paired serum samples, detection of viral antigen in both lower and upper respiratory tract samples 7, [13] [14] [15] [16] [17] , and viral culture for diagnosis of viral pneumonia. Therefore, we included influenza virus in the etiology of HCAP according to these reports. However, it is important to mention the methodology of relying on testing of nasopharyngeal specimens for diagnosis of viral pneumonia because a virus detected in the nasopharynx may simply represent the presence of an upper respiratory infection or pneumonia antigen. patients by RIDT and serology. However, a prospective study of Japanese nursing home residents reported detection of influenza virus in 14.7 of 75 cases by serology 11 , and influenza virus accounted for 9.0 of our cases. These results suggest that in uenza virus infection is not uncommon in HCAP, which may also be important information for infection control. To our knowledge, only one report has described the etiology of severe HCAP 19 . That report introduced the polymerase chain reaction PCR method for etiological diagnosis and showed that S. pneumoniae and S. aureus including MRSA were the most frequent pathogens, followed by Gram-negative enteric bacilli and P. aeruginosa. In uenza virus infection accounted for 4.5 of pathogens, slightly lower than our results but suggesting that in uenza virus infection is also not uncommon in severe HCAP. RIDT detected most of the cases of influenza virus infection in the patients with severe HCAP, whereas paired sera could only be obtained in 6 of 13 patients, indicating that when the diagnosis of in uenza virus infection is based only on paired sera, cases with an acute clinical course or early death can be missed. In the present study, disease severity was found to be an independent risk factor for mortality from HCAP. The three most widely studied criteria for severe pneumonia are the 20-variable Pneumonia Severity Index 20 , the 5-variable CURB-65 score the score is an acronym for each of the risk factors : Confusion, Urea 7 mmol / L, Respiratory rate ≥ 30 / min, low blood pressure, and Age ≥ 65 21 , and the 8-variable IDSA / ATS criteria 6 . We analyzed this study in accordance with the 8-variable IDSA / ATS criteria 6 , which is reported to have similar prognostic power to the Pneumonia Severity Index 20 in HCAP patients 22 , and disease severity on admission was identi ed as a prognostic factor for mortality from HCAP, as previously reported 23 .
We also found treatment failure of initial antibiotics to be associated with mortality. As addressed previously in the guidelines 1 , several factors relate to failure to improve, which include bacterial, host, and therapeutic factors. Because MDR pathogens are more common in HCAP than CAP and inappropriate initial antimicrobial therapy increases mortality 24, 25 , broad-spectrum coverage as empirical therapy has been recommended 1 . In the present study, the frequency of MDR pathogen infections was 9.8 , which was higher than that of CAP in our hospital 5 ,
indicating that patients requiring broad-spectrum therapy more frequently have HCAP than CAP. Further, MDR pathogens accounted for 21.3 of non-survivors, which suggests MDR pathogens to be important therapeutic targets to mitigate negative outcomes of HCAP. Falcone et al 26 showed that empirical broad-spectrum therapy was associated with improved outcome in patients with HCAP. However, Attridge et al 27 reported that guideline-concordant HCAP therapy is not associated with improved survival compared with guideline-concordant CAP therapy, in nonsevere HCAP. This result may be due to the high prevalence of culture-negative infections, which can be treated effectively following a CAP regimen 28, 29 , or to a low local prevalence of resistant pathogens 30 . Unfortunately, because none of our patients had received anti-MRSA therapy, we could not assess the relation between HCAP guideline-concordant therapy 1 and outcome. In addition, we found that there were still signi cant numbers of traditional CAP pathogens isolated in HCAP patients, as reported previously 31, 32 ; however, we could not statistically prove the efficacy of CAP treatment on mortality in HCAP. Further studies are needed to determine appropriate antibiotic selection. Early use of NIs can reduce development of complications such as pneumonia 33 , and current
Center for Disease Control guidelines recommend NIs for hospitalized patients with influenza virus infection 34 . We could not study the ef cacy of NIs on in uenza virus infection because of the small number of patients, and further studies are needed to clarify this matter in HCAP. In addition, Rosón et al 24 reported that factors other than inappropriate antibiotic selection are frequent causes of treatment failure and suggested that the capacity of antibiotic therapy to further reduce mortality may be limited 24 . In our study, 29.9 of patients with disease progression after initial antibiotic therapy had received appropriate therapy, and 5 of 10 non-survivors with MDR pathogen infection had received appropriate therapy. Similar studies have also been reported 35, 36 , and these ndings suggest that treatment strategies for HCAP other than antibiotic selection are also required. HCAP patients are often functionally disabled, and patient-related factors including functional status may be needed in the analysis of prognostic factors, which was dif cult in the present study due to its retrospective nature. We analyzed patients meeting the current HCAP criteria 1 . Because the risk of infection by an MDR pathogen is not equivalent for each criterion de ning HCAP 9 , the frequency of MDR pathogens may differ in accordance with the frequency of patients with each criterion. Differences in epidemiology of drug-resistant pathogens and healthcare and social health insurance systems among countries and regions should be taken into account. Park et al 9 reported a poor prediction of potentially drug-resistant pathogens in Korea, using the current HCAP criteria. In 2011, the Japanese Respiratory Society proposed a modi ed concept of HCAP called nursing and healthcare-associated pneumonia , considering the epidemiological and social environmental situations in Japan 37 . Ishida et al 38 revealed the usefulness of the guidelines in a prospective manner. To de ne better strategies and to mitigate negative outcomes from HCAP, further studies are needed to identify predictive factors of MDR pathogens and prognostic factors. The present study has several limitations. First, because it is a retrospective, observational, single-center study, the level of con dence is reduced, and the results may not be applicable in other settings. Second, a complete diagnostic workup to determine etiology was not possible in every patient. Third, we did not use PCR assay methods in the etiological diagnosis. Although PCR techniques are more labor intensive and technically demanding and require specialized laboratory equipment, PCR is sensitive, and some cases of in uenza or other virus, infection may have been missed.
In conclusion, in the patients with HCAP, the most frequent microbial agents were S. pneumoniae, P. aeruginosa, and in uenza virus. Disease severity and treatment failure of initial antibiotics were independent risk factors for mortality from HCAP. MDR pathogens are important therapeutic targets to mitigate negative results, and treatment strategies other than antibiotic selection are also required to reduce treatment failure.
